28
Participants
Start Date
June 30, 2009
Primary Completion Date
May 31, 2010
Study Completion Date
May 31, 2010
CXL-1020
Intravenous infusion of one of 3 active dosages of CXL-1020
CXL-1020
Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
Placebo for CXL-1020 Cohort 1
A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
Placebo for CXL-1020 Cohort 2
A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
CXL-1020 Dose for Echo Cohort A
A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
CXL-1020 Doses for Echo Cohort B
A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
Orange County Clinical Research Center, Tustin
Lead Sponsor
Collaborators (1)
Cardioxyl Pharmaceuticals, Inc
INDUSTRY
Bristol-Myers Squibb
INDUSTRY